Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

R. Bell, J. Brown, M. Parmar, M. Toi, T. Suter, G.G Steger, X. Pivot, J. Mackey, C. Jackisch, R. Dent, Peter Hall, N. Xu, L. Morales, L. Provencher, R. Hegg, L. Vanlemmens, A. Kirsch, A. Schneeweiss, N. Masuda, F. OverkampDavid Cameron

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalAnnals of Oncology
Early online date19 Dec 2016
DOIs
Publication statusE-pub ahead of print - 19 Dec 2016

Keywords

  • breast cancer
  • triple negative
  • chemotherapy
  • Bevacizumab
  • survival

Cite this